Pfizer strikes $1.2bn licensing deal for Biohaven migraine drug
pharmaphorum
NOVEMBER 10, 2021
The agreement includes a sizeable $500 million upfront payment, reflecting that Nurtec ODT (rimegepant) is already FDA-approved for treating acute migraine with and without aura in adults, and for prevention of episodic migraine in patients who suffer less than 15 headache days per month.
Let's personalize your content